Site Eiffel, 82 boulevard de la Moselle
78 articles with Novasep
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
Thermo Fisher Scientific announced the completion of Henogen SA, Groupe Novasep SAS’s viral vector manufacturing business in Belgium. The deal was for €725 million in cash.
1/7/2021Biopharma and life sciences companies from across the globe provide updates on their pipelines and business.
The life science company Sartorius announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep.
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, announced it has entered into an agreement to acquire the chromatography process equipment division of Novasep.
11/5/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
5/28/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
NOVASEP and LYSOGENE Announce Their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product
Novasep announced the signature of an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1 Gangliosidosis, a rare neuronopathic lysosomal storage disorder.
3/5/2020Life sciences companies from across the globe provide updates on their businesses and pipelines.
Leveraging on its recent investments Senrise-IV and Senefill, Novasep launches a unique 2-year turnkey plant offer to accelerate commercial production of viral vectors.
Senefill, Novasep's Commercial Facility for Aseptic Filling and Finishing Operations, Is Now Ready to Operate
Senefill will be commissioned on October 1, 2019 and will offer Fill & Finish clinical and commercial services for biological products, from formulation to packaging
NOVASEP and THERAVECTYS Enter Into a New License Agreement on DNA Flap Technology for GMP Manufacturing of Lentiviral Vectors
Novasep, today announced the signing of a license agreement allowing Novasep to use Institut Pasteur's DNA Flap Technology to produce GMP-grade lentiviral vectors for clinical use in all therapeutic applications including gene therapy, cell therapy, immunotherapy and vaccination, for any customer, worldwide
This company is a recognized system provider with substantial expertise in the design, manufacture and control of resin-based batch and continuous chromatography systems.
Enzene Biosciences Chooses Novasep BioSC® Pilot Chromatography for Its Automated End to End Continuous Manufacture of mAb
Novasep, a leading supplier of services and technologies for the life sciences industry, announces Enzene Biosciences (India) has chosen BioSC® Pilot for purification of biopharmaceuticals to operate in its Pune plant.
This represents a step forward for the plant-based protein purification industry, with the first compact bed chromatography system for the purification of vegetable proteins
Novasep is proud to announce that its API development and manufacturing site in Chasse-sur-Rhone, France, has been successfully inspected by the US Food and Drug Administration (FDA)
BioSC® Pilot is a new tool for continuous and intensified downstream processes in the biopharmaceutical industry.
Novasep Invests €10M in "SeneFill", Its New Facility for Commercial Aseptic Fill & Finish Operations
Novasep announces a EUR10M investment in a commercial fill & finish facility for viral vectors, mAbs and other low-volume biologics.
Novasep Signs Manufacturing Agreement With Clinical-Stage Biopharmaceutical Company Tetraphase for Eravacycline API
This manufacturing agreement with Tetraphase is the result of a successful collaboration that started in 2014 with the clinical supply of eravacycline.
Novasep announces a EUR17M investment in a dedicated GMP mAb production facility.